About Ronald HW Lorijn

Highly skilled professional motivated by competition and stimulating interactions, makes quick decisions. Aptly work under pressure, is determined to succeed and pours energy into getting a productive outcome. Enjoys interacting with and motivating people around organizational activities. Proven Leadership and team building capabilities creating new or expanding existing business. His experience spans the continuum from drug discovery to commercialization. Executive management positions include Director and VP positions with Centocor and Amgen. As CEO of AMT he successful guided the company’s IPO (Euronext), raising gross proceeds of EUR 55.7 million one year after closing of its €22 million private placement financing (series A round) with four top tier venture capital firms. At this time, Lorijn manages and builds up with his team NeuExcell Therapeutics, a gene therapy company leading the field of neurodegenerative diseases.